Companies / Grace Therapeutics, Inc.

Grace Therapeutics, Inc.

Nasdaq: GRCECIK 1444192PRINCETON, NJ

Financials · FY2023

Revenue$100.00M
Net income$-7.79M
Total debt
Cash$13.76M
Diluted EPS$-0.47
Shares outstanding21.0M

Ownership

21.0M shares outstanding · as of Aug 11, 2026
13.1%10%+ / strategic
Ownership
10%+ / strategic13.07%2,748,392
Institutions21.81%4,587,271
Public float65.13%13,700,267

% of common shares outstanding (exact, from the latest cover-page filing). Institutions are quarterly 13F snapshots; insiders reflect current officers & directors.

Insiders 4

View all →
Insider% of sharesShares
Davis a BrianFormerDirector
Kavuru VimalFormerDirector
Kottayil GeorgeFormerDirector
Neugeboren EdwardFormerDirector

Institutional holders 25

View all →

Activity

Jun 30, 2026View all →
InsidersInstitutions
Who's accumulating and trimming this stock (13F).
DateActorActionSecurityValueShares ΔPosition afterImpact
Q2 2026
as of
AIGH Capital Management LLC
13F manager
ExitCommon stock$-3.15M-907K
-100.00%
0
low
Q1 2026
as of
Renaissance Technologies LLC
13F manager
AddCommon stock$528.4K+114K
+87.94%
243,910
1.16% of shares
low
Q1 2026
as of
Marshall Wace, LLP
13F manager
NewCommon stock$423.3K+91K
91,416
0.43% of shares
low
Q2 2026
as of
BlackRock, Inc.
13F manager
NewCommon stock$85.2K+38K
37,535
0.18% of shares
low
Q1 2026
as of
Prelude Capital Management, LLC
13F manager
NewCommon stock$46.6K+10K
10,074
0.05% of shares
low
Q1 2026
as of
BNP Paribas Financial Markets
13F manager
AddCommon stock$30.1K+7K
+1083.33%
7,100
0.03% of shares
low
Q1 2026
as of
Gsa Capital Partners LLP
13F manager
ExitCommon stock$-48-14K
-100.00%
0
low

5%+ ownership events

Schedule 13D / 13G
FilerStance% of classSharesDate
Opaleye Management Inc.Passive13G2,748,392
Orin HirschmanPassive13G/A
Nantahala Capital Management, LLCPassive13G/A
ADAR1 Capital Management, LLCPassive13G/A
Orin HirschmanPassive13G/A

Securities

via CUSIP / OpenFIGI
SymbolTypeMarketCUSIPFIGI
GRCE00439U104